<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03802864</url>
  </required_header>
  <id_info>
    <org_study_id>1802018993</org_study_id>
    <nct_id>NCT03802864</nct_id>
  </id_info>
  <brief_title>Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine</brief_title>
  <official_title>Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a drug trial comparing the post-operative pain control provided by liposomal
      bupivacaine (a local anesthetic) against standard bupivacaine (a different formulation of the
      local anesthetic) for men undergoing testicular sperm extraction.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study model is a randomized double blind control trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain scores 48 hours after surgery</measure>
    <time_frame>First 48 hours after surgery</time_frame>
    <description>Area under the curve of pain rankings on the 11-point numerical pain rating scales (0 indicating no pain and 10 indicating worst possible pain) assessed every 8 hours in the first 48 hours post-surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores 60 hours after surgery</measure>
    <time_frame>First 60 hours after surgery</time_frame>
    <description>Area under the curve of pain rankings on the 11-point numerical pain rating scales (0 indicating no pain and 10 indicating worst possible pain) assessed twice daily in the first 60 hours post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores 7 days after surgery</measure>
    <time_frame>First 7 days after surgery</time_frame>
    <description>Area under the curve of pain rankings on the 11-point numerical pain rating scales (0 indicating no pain and 10 indicating worst possible pain) assessed twice daily in the first 7 days post-surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Narcotic requirement</measure>
    <time_frame>First 7 days after surgery</time_frame>
    <description>Total number of narcotic tablets required between the intervention and control arms during post-operative day 1 through 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to narcotic rescue</measure>
    <time_frame>First 7 days after surgery</time_frame>
    <description>Time (in hours) to first rescue narcotic utilization between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control satisfaction</measure>
    <time_frame>7th day after surgery</time_frame>
    <description>Overall satisfaction of pain control regimen self reported on post-operative day 7. The prompt will be a yes/no answer. The percent of participants answering &quot;yes&quot; will be compared between the two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients not requiring any narcotics</measure>
    <time_frame>7th day after surgery</time_frame>
    <description>The percentage of patients remaining opiate free by post-operative day 7.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Male Infertility</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will have a single injection of liposomal bupivacaine admixed with standard bupivacaine (266mg liposomal bupivacaine mixed with 50mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in this arm will have a single injection of standard bupivacaine (100mg bupivacaine hydrochloride) at the conclusion of their surgical sperm retrieval procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>After surgical sperm retrieval, the wound will be injected with liposomal bupivacaine (266 mg) mixed with standard bupivacaine (bupivacaine hydrochloride 50mg) for post-operative pain relief.</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Bupivacaine</intervention_name>
    <description>After surgical sperm retrieval, the wound will be injected only with standard bupivacaine (bupivacaine hydrochloride 100mg) for post-operative pain relief.</description>
    <arm_group_label>Standard Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men scheduled for surgical sperm retrieval for infertility

          -  Men 18 years and older who can provide informed consent

          -  No documented allergy to bupivacaine or celecoxib

        Exclusion Criteria:

          -  Prior history of substance abuse

          -  Any narcotic use within the last 3 months

          -  Concomitant use of aspirin

          -  Any of the following comorbidities: renal failure, heart disease, peptic ulcer
             disease, cerebrovascular disease, significant liver disease, untreated depression,
             chronic pain disorder, or bleeding diatheses

          -  Medical history or concurrent illness that the investigator considers sufficiently
             serious to interfere with the conduct, completion, or results of this trial, or
             constitutes an unacceptable risk to the subject
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Russell Hayden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medicine Department of Urology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

